Hiroki Ozawa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Hiroki Ozawa has a total of 115 co-authors. Here are the top co-authors by number of shared publications:
- Donald Kufe
Department of Medical Oncology, Dana-Farber Cancer Institute Harvard Medical School, Boston, Massachusetts
53 shared publications - Mark D. Long
Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA
50 shared publications - Atrayee Bhattacharya
Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts
47 shared publications - Keisuke Shigeta
Department of Urology Keio University School of Medicine Tokyo Japan
47 shared publications - Ayako Nakashoji
Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA
36 shared publications - Ann Marie Egloff
Brigham and Women's Hospital, Boston, MA, United States
35 shared publications
Latest Publications
- Open Access
- 5 August 2026
- Published by Springer Nature in Oncogene
- Vol. 45 (38) , 4088-4100
M1C is a druggable target for NSCLC KRAS G12C mutant tumors resistant to KRAS inhibitors
Treatment of NSCLC KRAS G12C mutant tumors with the allele-selective sotorasib and adagrasib inhibitors is invariably associated with acquired resistance. The MUC1-encoded oncogenic M1C protein is necessary for self-renewal of NSCLC KRAS mutant cells. We report that treatment of NSCLC KRAS G12C cells with sotorasib induces M1C expression by a STAT1-dependent pathway. In turn, M1C drives the sotorasib resistant phenotype by NF-κB-mediated induction of the epithelial-mesenchymal transition (EMT) and a mucinous gene program. Targeting M1C→NF-κB signaling (i) suppresses EMT and mucin genes, and (ii) reverses sotorasib resistance. Of translational relevance, treatment with a M1C antibody-drug conjugate (ADC) is effective against two sotorasib-resistant NSCLC KRAS G12C cell lines and two patient-derived tumor xenograft models. Analysis of patients with NSCLC KRAS G12C tumors treated with sotorasib/adagrasib and overexpressing MUC1 associates with decreases in overall survival. These findings identify M1C as a key effector of sotorasib resistance and as a target for treatment of patients with refractory NSCLC KRAS G12C mutant tumors.
- 5 August 2026
- Published by Springer Nature in Oncogene
- Vol. 45 (38) , 4088-4100
Open AccessM1C is a druggable target for NSCLC KRAS G12C mutant tumors resistant to KRAS inhibitors
Treatment of NSCLC KRAS G12C mutant tumors with the allele-selective sotorasib and adagrasib inhibitors is invariably associated with acquired resistance. The MUC1-encoded oncogenic M1C protein is necessary for self-renewal of NSCLC KRAS mutant cells. We report that treatment of NSCLC KRAS G12C cells with sotorasib induces M1C expression by a STAT1-dependent pathway. In turn, M1C drives the sotorasib resistant phenotype by NF-κB-mediated induction of the epithelial-mesenchymal transition (EMT) and a mucinous gene program. Targeting M1C→NF-κB signaling (i) suppresses EMT and mucin genes, and (ii) reverses sotorasib resistance. Of translational relevance, treatment with a M1C antibody-drug conjugate (ADC) is effective against two sotorasib-resistant NSCLC KRAS G12C cell lines and two patient-derived tumor xenograft models. Analysis of patients with NSCLC KRAS G12C tumors treated with sotorasib/adagrasib and overexpressing MUC1 associates with decreases in overall survival. These findings identify M1C as a key effector of sotorasib resistance and as a target for treatment of patients with refractory NSCLC KRAS G12C mutant tumors.
- 12 February 2026
- Published by Elsevier in Cancer Letters
- Vol. 644, 218320
M1C mediates LINE-1 transcription in PARP inhibitor-treated prostate cancer cells
- 12 February 2026
- Published by Elsevier in Cancer Letters
- Vol. 644, 218320
M1C mediates LINE-1 transcription in PARP inhibitor-treated prostate cancer cells
- Open Access
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S5 from Targeting KRAS Inhibitor–Resistant Pancreatic Cancer with an MUC1-C Antibody–Drug Conjugate
Supplemental Figure S5. M1C regulates IFN type I/II pathway genes. A-D. Analysis of genes significantly (i) upregulated in AsPC-1/MR vs AsPC-1 cells, and (ii) downregulated in AsPC-1/MR cells with M1C silencing using the HALLMARK INTERFERON ALPHA (A,B) and GAMMA (C,D) gene signatures. Violin plots illustrate the distribution of mean Z-scores for each gene signature. Group differences were determined by multivariate testing using meta-scores. E and F. Lysates from AsPC-1 (E) and PANC-1 (F) cells expressing the indicated vectors and treated with vehicle or DOX for 7 days, followed by vehicle or 50 nM (E) and 1 µM (F) MRTX-1133 for 2 days were immunoblotted with antibodies against the indicated proteins. G. AsPC-1/MR/CshRNA and AsPC-1/MR/MUC1shRNA#2 cells treated with 1 μM MRTX1133 for 6 days were analyzed for colony formation. Shown are representative photomicrographs of stained colonies. H. PANC-1/MR/CshRNA and PANC-1/MR/MUC1shRNA#2 cells treated with 1 μM MRTX1133 for 6 days were analyzed for colony formation. Shown are representative photomicrographs of stained colonies. I. Lysates from AsPC-1/MR/CshRNA, AsPC-1/MR/STAT1shRNA#1 and AsPC-1/MR/STAT1shRNA#2 were immunoblotted with antibodies against the indicated proteins. J. Lysates from PANC-1/MR/CshRNA, PANC-1/MR/STAT1shRNA#1 and PANC-1/MR/STAT1shRNA#2 were immunoblotted with antibodies against the indicated proteins. K. AsPC-1/MR/CshRNA, AsPC-1/MR/STAT1shRNA#1, AsPC-1/MR/STAT1shRNA#2 cells treated with 1 μM MRTX1133 for 6 days were analyzed for colony formation. Shown are representative photomicrographs of stained colonies. L. PANC-1/MR/CshRNA, PANC-1/MR/STAT1shRNA#1, PANC-1/MR/STAT1shRNA#2 cells treated with 1 μM MRTX1133 for 6 days were analyzed for colony formation. Shown are representative photomicrographs of stained colonies. M. AsPC-1/MR/CshRNA, AsPC-1/MR/STAT1shRNA#1 and AsPC-1/MR/STAT1shRNA#2 cells treated with the indicated concentrations of MRTX1133 for 3 days were analyzed for cell viability by Alamar Blue staining. The results (mean±SD of four determinations) are expressed as relative cell number compared to that for CshRNA cells (assigned a value of 1). N. PANC-1/MR/CshRNA, PANC-1/MR/STAT1shRNA#1 and PANC-1/MR/STAT1shRNA#2 cells treated with the indicated concentrations of MRTX1133 for 3 days were analyzed for cell viability by Alamar Blue staining. The results (mean±SD of four determinations) are expressed as relative cell number compared to that for CshRNA cells (assigned a value of 1).
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Targeting KRAS Inhibitor–Resistant Pancreatic Cancer with an MUC1-C Antibody–Drug Conjugate
Supplemental Figure S5. M1C regulates IFN type I/II pathway genes. A-D. Analysis of genes significantly (i) upregulated in AsPC-1/MR vs AsPC-1 cells, and (ii) downregulated in AsPC-1/MR cells with M1C silencing using the HALLMARK INTERFERON ALPHA (A,B) and GAMMA (C,D) gene signatures. Violin plots illustrate the distribution of mean Z-scores for each gene signature. Group differences were determined by multivariate testing using meta-scores. E and F. Lysates from AsPC-1 (E) and PANC-1 (F) cells expressing the indicated vectors and treated with vehicle or DOX for 7 days, followed by vehicle or 50 nM (E) and 1 µM (F) MRTX-1133 for 2 days were immunoblotted with antibodies against the indicated proteins. G. AsPC-1/MR/CshRNA and AsPC-1/MR/MUC1shRNA#2 cells treated with 1 μM MRTX1133 for 6 days were analyzed for colony formation. Shown are representative photomicrographs of stained colonies. H. PANC-1/MR/CshRNA and PANC-1/MR/MUC1shRNA#2 cells treated with 1 μM MRTX1133 for 6 days were analyzed for colony formation. Shown are representative photomicrographs of stained colonies. I. Lysates from AsPC-1/MR/CshRNA, AsPC-1/MR/STAT1shRNA#1 and AsPC-1/MR/STAT1shRNA#2 were immunoblotted with antibodies against the indicated proteins. J. Lysates from PANC-1/MR/CshRNA, PANC-1/MR/STAT1shRNA#1 and PANC-1/MR/STAT1shRNA#2 were immunoblotted with antibodies against the indicated proteins. K. AsPC-1/MR/CshRNA, AsPC-1/MR/STAT1shRNA#1, AsPC-1/MR/STAT1shRNA#2 cells treated with 1 μM MRTX1133 for 6 days were analyzed for colony formation. Shown are representative photomicrographs of stained colonies. L. PANC-1/MR/CshRNA, PANC-1/MR/STAT1shRNA#1, PANC-1/MR/STAT1shRNA#2 cells treated with 1 μM MRTX1133 for 6 days were analyzed for colony formation. Shown are representative photomicrographs of stained colonies. M. AsPC-1/MR/CshRNA, AsPC-1/MR/STAT1shRNA#1 and AsPC-1/MR/STAT1shRNA#2 cells treated with the indicated concentrations of MRTX1133 for 3 days were analyzed for cell viability by Alamar Blue staining. The results (mean±SD of four determinations) are expressed as relative cell number compared to that for CshRNA cells (assigned a value of 1). N. PANC-1/MR/CshRNA, PANC-1/MR/STAT1shRNA#1 and PANC-1/MR/STAT1shRNA#2 cells treated with the indicated concentrations of MRTX1133 for 3 days were analyzed for cell viability by Alamar Blue staining. The results (mean±SD of four determinations) are expressed as relative cell number compared to that for CshRNA cells (assigned a value of 1).
- Open Access
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S8 from Targeting KRAS Inhibitor–Resistant Pancreatic Cancer with an MUC1-C Antibody–Drug Conjugate
Supplemental Figure S8. Analysis of patient-derived organoids for M1C expression and sensitivity to the M1C ADC. A and B. Lysates from PF108 (A) and PF405 (B) cells treated with 1 μM MRTX1133 for 2 days were immunoblotted with antibodies against the indicated proteins. C. Patient-derived organoids treated with the indicated M1C ADC concentrations for 6 days were analyzed for cell viability by CellTiter-Glo 3D Cell Viability Assay. The results (mean±SD of five determinations) are expressed as relative cell number (% control) compared to that for untreated cells. Indicated are the M1C ADC IC50 values. D. Patient-derived organoids were treated with the indicated concentrations of M1C ADC and MRTX1133 for 6 days. Cell viability was assessed using the CellTiter-Glo 3D Cell Viability Assay (mean of five determinations). Indicated are the combination indices determined using Bliss scores.
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from Targeting KRAS Inhibitor–Resistant Pancreatic Cancer with an MUC1-C Antibody–Drug Conjugate
Supplemental Figure S8. Analysis of patient-derived organoids for M1C expression and sensitivity to the M1C ADC. A and B. Lysates from PF108 (A) and PF405 (B) cells treated with 1 μM MRTX1133 for 2 days were immunoblotted with antibodies against the indicated proteins. C. Patient-derived organoids treated with the indicated M1C ADC concentrations for 6 days were analyzed for cell viability by CellTiter-Glo 3D Cell Viability Assay. The results (mean±SD of five determinations) are expressed as relative cell number (% control) compared to that for untreated cells. Indicated are the M1C ADC IC50 values. D. Patient-derived organoids were treated with the indicated concentrations of M1C ADC and MRTX1133 for 6 days. Cell viability was assessed using the CellTiter-Glo 3D Cell Viability Assay (mean of five determinations). Indicated are the combination indices determined using Bliss scores.
- Open Access
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S7 from Targeting KRAS Inhibitor–Resistant Pancreatic Cancer with an MUC1-C Antibody–Drug Conjugate
Supplemental Figure S7. ST-00013312-T cells are sensitive to treatment with the M1C ADC. A. AsPC-1/MR cells cultured in the absence of MRTX1133 for 30 days and then with the indicated concentrations of MRTX1133 for 3 days were analyzed for cell viability by Alamar Blue staining. The results (mean±SD of six determinations) are expressed as relative cell number (% control) compared to that for untreated cells. Indicated is the MRTX1133 IC50 value. B. Mean body weight changes of the AsPC-1/MR tumor bearing mice treated with vehicle or M1C ADC. The results are expressed as the mean ratio of relative body weight ± SEM. C. Mean body weight changes of the PANC-1/MR tumor bearing mice treated with vehicle or M1C ADC. The results are expressed as the mean ratio of relative body weight ± SEM. D. ST-00013312-T cells treated with the indicated concentrations of MRTX1133 for 3 days were analyzed for cell viability by Alamar Blue staining. The results (mean±SD of six determinations) are expressed as relative cell number (% control) compared to that for untreated cells. Indicated is the MRTX1133 IC50 value. E. ST-00013312-T cells treated with vehicle, 5 µM GO-203 and 1 µM MRTX1133 for 6 days were analyzed for colony formation. Shown are representative photomicrographs of stained colonies. F. ST-00013312-T cells treated with the indicated concentrations of M1C ADC for 6 days were analyzed for cell viability by Alamar Blue staining. The results (mean±SD of four determinations) are expressed as relative cell number (% control) compared to that for untreated cells. Indicated is the M1C ADC IC50 value. G. ST-00013312-T cells treated with vehicle, 50 nM M1C ADC and 1 µM MRTX1133 for 6 days were analyzed for colony formation. Shown are representative photomicrographs of stained colonies. H. Mean body weight changes of ST-00013312-T tumor bearing mice treated with vehicle or M1C ADC. The results are expressed as the mean ratio of relative body weight ± SEM.
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from Targeting KRAS Inhibitor–Resistant Pancreatic Cancer with an MUC1-C Antibody–Drug Conjugate
Supplemental Figure S7. ST-00013312-T cells are sensitive to treatment with the M1C ADC. A. AsPC-1/MR cells cultured in the absence of MRTX1133 for 30 days and then with the indicated concentrations of MRTX1133 for 3 days were analyzed for cell viability by Alamar Blue staining. The results (mean±SD of six determinations) are expressed as relative cell number (% control) compared to that for untreated cells. Indicated is the MRTX1133 IC50 value. B. Mean body weight changes of the AsPC-1/MR tumor bearing mice treated with vehicle or M1C ADC. The results are expressed as the mean ratio of relative body weight ± SEM. C. Mean body weight changes of the PANC-1/MR tumor bearing mice treated with vehicle or M1C ADC. The results are expressed as the mean ratio of relative body weight ± SEM. D. ST-00013312-T cells treated with the indicated concentrations of MRTX1133 for 3 days were analyzed for cell viability by Alamar Blue staining. The results (mean±SD of six determinations) are expressed as relative cell number (% control) compared to that for untreated cells. Indicated is the MRTX1133 IC50 value. E. ST-00013312-T cells treated with vehicle, 5 µM GO-203 and 1 µM MRTX1133 for 6 days were analyzed for colony formation. Shown are representative photomicrographs of stained colonies. F. ST-00013312-T cells treated with the indicated concentrations of M1C ADC for 6 days were analyzed for cell viability by Alamar Blue staining. The results (mean±SD of four determinations) are expressed as relative cell number (% control) compared to that for untreated cells. Indicated is the M1C ADC IC50 value. G. ST-00013312-T cells treated with vehicle, 50 nM M1C ADC and 1 µM MRTX1133 for 6 days were analyzed for colony formation. Shown are representative photomicrographs of stained colonies. H. Mean body weight changes of ST-00013312-T tumor bearing mice treated with vehicle or M1C ADC. The results are expressed as the mean ratio of relative body weight ± SEM.
- Open Access
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table S1 from Targeting KRAS Inhibitor–Resistant Pancreatic Cancer with an MUC1-C Antibody–Drug Conjugate
Primers used for qRT-PCR analysis.
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table S1 from Targeting KRAS Inhibitor–Resistant Pancreatic Cancer with an MUC1-C Antibody–Drug Conjugate
Primers used for qRT-PCR analysis.
- Open Access
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S3 from Targeting KRAS Inhibitor–Resistant Pancreatic Cancer with an MUC1-C Antibody–Drug Conjugate
Supplemental Figure S3. M1C regulates KRAS signaling pathway genes in the PDAC MRTX1133-resistant phenotype. A and B. Scatter plots of genes regulated in AsPC-1 and AsPC-1/MR cells with M1C silencing using the HALLMARK KRAS UP (A) and DN (B) genes signatures.
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Targeting KRAS Inhibitor–Resistant Pancreatic Cancer with an MUC1-C Antibody–Drug Conjugate
Supplemental Figure S3. M1C regulates KRAS signaling pathway genes in the PDAC MRTX1133-resistant phenotype. A and B. Scatter plots of genes regulated in AsPC-1 and AsPC-1/MR cells with M1C silencing using the HALLMARK KRAS UP (A) and DN (B) genes signatures.
- Open Access
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from Targeting KRAS Inhibitor–Resistant Pancreatic Cancer with an MUC1-C Antibody–Drug Conjugate
Supplemental Figure S1. MRTX1133 induces an M1C/NF-kB p65 pathway that regulates ALPPL2 expression. A and B. Volcano plots depicting downregulated and upregulated genes in AsPC-1 cells treated with MRTX1133 vs control in vitro (A) and as tumor xenografts (B). Highlighted are MUC1 and ALPG. C. Lysates from HPAF-II cells treated with 10 nM MRTX1133 for 2 days were immunoblotted with antibodies against the indicated proteins. D. Lysates from AsPC-1 KRAS G12D and PANC-1 KRAS G12D cells treated with the indicated RMC-6236 concentrations for 2 days were immunoblotted with antibodies against the indicated proteins. E. Lysates from CFPAC-1 KRAS G12V and MiaPaCa KRAS G12C cells treated RMC-6236 or MRTX1133 for 2 days were immunoblotted with antibodies against the indicated proteins. F. Cytosolic, cell membrane, soluble nucleoplasm and chromatin fractions from AsPC-1 cells left untreated or treated with 50 nM MRTX1133 for 2 days were immunoblotted with antibodies against the indicated proteins. G. Association of MUC1 and NF-kB p65/RELA in the TCGA-PDAC/PAAD dataset. H and I. Lysates from AsPC-1 (H) and PANC-1 (I) cells treated with 2.5 μM BAY-11 and 50 nM or 1 µM MRTX1133 for 2 days were immunoblotted with antibodies against the indicated proteins. J. Lysates from AsPC-1/CshRNA, AsPC-1/STAT1shRNA#1 and AsPC-1/STAT1shRNA#2 treated with 50 nM MRTX1133 for 2 days were immunoblotted with antibodies against the indicated proteins. K. Lysates from PANC-1 cells treated with 1 μM MRTX1133 for 2 and 6 days were immunoblotted with antibodies against the indicated proteins. L. Lysates from PANC-1 cells expressing the indicated vectors and treated with DOX for 7 days were immunoblotted with antibodies against the indicated proteins. M. Lysates from AsPC-1 cells expressing a CshRNA or NF-kBshRNA and treated with 50 nM MRTX1133 for 2 days were immunoblotted with antibodies against the indicated proteins. N. Lysates from AsPC-1 cells treated with 2.5 μM BAY-11 and 50 nM MRTX1133 for 2 days were immunoblotted with antibodies against the indicated proteins.
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Targeting KRAS Inhibitor–Resistant Pancreatic Cancer with an MUC1-C Antibody–Drug Conjugate
Supplemental Figure S1. MRTX1133 induces an M1C/NF-kB p65 pathway that regulates ALPPL2 expression. A and B. Volcano plots depicting downregulated and upregulated genes in AsPC-1 cells treated with MRTX1133 vs control in vitro (A) and as tumor xenografts (B). Highlighted are MUC1 and ALPG. C. Lysates from HPAF-II cells treated with 10 nM MRTX1133 for 2 days were immunoblotted with antibodies against the indicated proteins. D. Lysates from AsPC-1 KRAS G12D and PANC-1 KRAS G12D cells treated with the indicated RMC-6236 concentrations for 2 days were immunoblotted with antibodies against the indicated proteins. E. Lysates from CFPAC-1 KRAS G12V and MiaPaCa KRAS G12C cells treated RMC-6236 or MRTX1133 for 2 days were immunoblotted with antibodies against the indicated proteins. F. Cytosolic, cell membrane, soluble nucleoplasm and chromatin fractions from AsPC-1 cells left untreated or treated with 50 nM MRTX1133 for 2 days were immunoblotted with antibodies against the indicated proteins. G. Association of MUC1 and NF-kB p65/RELA in the TCGA-PDAC/PAAD dataset. H and I. Lysates from AsPC-1 (H) and PANC-1 (I) cells treated with 2.5 μM BAY-11 and 50 nM or 1 µM MRTX1133 for 2 days were immunoblotted with antibodies against the indicated proteins. J. Lysates from AsPC-1/CshRNA, AsPC-1/STAT1shRNA#1 and AsPC-1/STAT1shRNA#2 treated with 50 nM MRTX1133 for 2 days were immunoblotted with antibodies against the indicated proteins. K. Lysates from PANC-1 cells treated with 1 μM MRTX1133 for 2 and 6 days were immunoblotted with antibodies against the indicated proteins. L. Lysates from PANC-1 cells expressing the indicated vectors and treated with DOX for 7 days were immunoblotted with antibodies against the indicated proteins. M. Lysates from AsPC-1 cells expressing a CshRNA or NF-kBshRNA and treated with 50 nM MRTX1133 for 2 days were immunoblotted with antibodies against the indicated proteins. N. Lysates from AsPC-1 cells treated with 2.5 μM BAY-11 and 50 nM MRTX1133 for 2 days were immunoblotted with antibodies against the indicated proteins.
- Open Access
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Data from Targeting KRAS Inhibitor–Resistant Pancreatic Cancer with an MUC1-C Antibody–Drug Conjugate
Purpose:Treatment of pancreatic ductal adenocarcinoma (PDAC) has been advanced by the development of KRAS inhibitors. Despite this progress, PDAC invariably develop resistance to these agents through multiple mechanisms. In this study, we investigated the role of the oncogenic MUC1-C (M1C) protein in mediating the resistance of PDAC cells to KRAS inhibition.Experimental Design:Three PDAC KRAS G12D–mutant cell lines, as well as patient-derived KRAS inhibitor–resistant organoids and patient-derived xenograft models, were investigated in these studies. An anti-M1C antibody–drug conjugate (ADC) was evaluated for in vitro and in vivo activity. Tumors from patients with PDAC were studied by single-cell RNA sequencing and IHC staining.Results:The MUC1 gene is upregulated in PDAC KRAS G12D–mutant tumors. We report that treatment of PDAC cells with the KRAS G12D inhibitor MRTX1133 is associated with the induction of the M1C protein. Mechanistically, KRAS G12D inhibition induces M1C by activation of an M1C/NF-κB p65 autoinductive pathway. Our results further demonstrate that M1C drives resistance to MRTX1133 by activating the inflammatory IFN type I pathway. Targeting M1C genetically and pharmacologically thereby reverses MRTX1133 resistance and is synergistic in combination with MRTX1133 treatment. Of translational significance, we demonstrate that an anti-M1C ADC is highly effective against MRTX1133-resistant PDAC KRAS G12D cell lines and patient-derived organoid and patient-derived xenograft models.Conclusions:These findings demonstrate that M1C confers resistance of PDAC to KRAS G12D inhibition and identify M1C as a potential target for ADC treatment of patients with PDAC who are refractory to KRAS inhibitors.
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Targeting KRAS Inhibitor–Resistant Pancreatic Cancer with an MUC1-C Antibody–Drug Conjugate
Purpose:Treatment of pancreatic ductal adenocarcinoma (PDAC) has been advanced by the development of KRAS inhibitors. Despite this progress, PDAC invariably develop resistance to these agents through multiple mechanisms. In this study, we investigated the role of the oncogenic MUC1-C (M1C) protein in mediating the resistance of PDAC cells to KRAS inhibition.Experimental Design:Three PDAC KRAS G12D–mutant cell lines, as well as patient-derived KRAS inhibitor–resistant organoids and patient-derived xenograft models, were investigated in these studies. An anti-M1C antibody–drug conjugate (ADC) was evaluated for in vitro and in vivo activity. Tumors from patients with PDAC were studied by single-cell RNA sequencing and IHC staining.Results:The MUC1 gene is upregulated in PDAC KRAS G12D–mutant tumors. We report that treatment of PDAC cells with the KRAS G12D inhibitor MRTX1133 is associated with the induction of the M1C protein. Mechanistically, KRAS G12D inhibition induces M1C by activation of an M1C/NF-κB p65 autoinductive pathway. Our results further demonstrate that M1C drives resistance to MRTX1133 by activating the inflammatory IFN type I pathway. Targeting M1C genetically and pharmacologically thereby reverses MRTX1133 resistance and is synergistic in combination with MRTX1133 treatment. Of translational significance, we demonstrate that an anti-M1C ADC is highly effective against MRTX1133-resistant PDAC KRAS G12D cell lines and patient-derived organoid and patient-derived xenograft models.Conclusions:These findings demonstrate that M1C confers resistance of PDAC to KRAS G12D inhibition and identify M1C as a potential target for ADC treatment of patients with PDAC who are refractory to KRAS inhibitors.
- Open Access
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data1 from Targeting KRAS Inhibitor–Resistant Pancreatic Cancer with an MUC1-C Antibody–Drug Conjugate
Supplemental Figure Legends and Supplemental Tables
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data1 from Targeting KRAS Inhibitor–Resistant Pancreatic Cancer with an MUC1-C Antibody–Drug Conjugate
Supplemental Figure Legends and Supplemental Tables